What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) , an estimated $5.43 million trade based on quarterly average pricing. Acco…
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) , an estimated $5.43 millio
Read Full Story at Yahoo Finance →Why This Matters
The investment signals a bet on Ultragenyx’s long-term pipeline despite its headline stock performance, suggesting institutional confidence in the company’s rare disease therapies. Given the fund’s track record of contrarian plays, this purchase may indicate an undervaluation thesis that could ripple through biotech investment circles.
Background Context
Ultragenyx has faced volatility tied to regulatory setbacks and pipeline delays, including a 2025 CRL for its gene therapy program that exacerbated investor skittishness. The 30% decline over the past year contrasts with a broader biotech sector recovery, underscoring the company’s idiosyncratic risks.
What Happens Next
If the fund’s thesis plays out, it could catalyze a reappraisal of Ultragenyx’s mid-stage assets among peers, particularly if upcoming data readouts meet expectations. Conversely, further delays or safety signals could test the fund’s conviction and prompt sector-wide reconsideration of rare disease betas.
Bigger Picture
This move reflects a growing appetite among allocators for high-conviction, high-risk biotech plays amid liquidity constraints in the sector. It also highlights how concentrated bets by specialized funds can shape sentiment before broader market validation materializes.
